Back to top

Analyst Blog

Zacks Equity Research

Dr. Reddy's Launches Generic Propecia

RDY MRK MYL

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dr. Reddy's Laboratories Ltd. (RDY - Snapshot Report) recently announced that it has launched its generic version of Merck & Co., Inc.’s (MRK - Analyst Report) Propecia (finasteride) 1 mg. The company will enjoy 180-days of marketing exclusivity in the US.

Propecia is approved for the treatment of male pattern hair loss. According to IMS Health, Propecia generated US revenues of approximately $136 million for the 12 months ending October 31, 2012.

At the end of the last quarter, Dr. Reddy’s had 63 ANDAs pending approval with the FDA, of which 33 are Para IV filings and 7 are first-to-file.

Dr. Reddy’s Global Generics segment revenues jumped 25% to $380 million in the last quarter. Generics revenue soared in North America (up 47%), driven by limited competition.

Revenues were also boosted by products from Shreveport facility and the ramp-up in the antibiotics portfolio. Generics revenues also increased in Russia and other CIS (Commonwealth of Independent States) markets (up 14%), India (up 12%) and the rest of the world/RoW (up 50%). However, generic revenues declined 16% in Europe due to disappointing performance in Germany.

Our Recommendation

We are pleased with Dr. Reddy’s geographic reach and product depth. Dr. Reddy’s also has a robust generic product pipeline. However, the company’s performance in Europe due to the continued economic weakness remains a concern.

During the period of 2017-2018, most of the large branded drugs are due to lose patent exclusivity and so we have little visibility on the growth prospects of generic companies like Dr. Reddy’s beyond that timeframe.

In view of these challenges, we see limited upside from current levels and maintain a Neutral recommendation on Dr. Reddy’s. The stock carries a Zacks #3 Rank (Hold) in the short run.

Mylan Inc. (MYL - Analyst Report), another generic player, currently holds a Zacks #2 Rank (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%